<DOC>
	<DOC>NCT01063829</DOC>
	<brief_summary>The aim of the study is to find out whether AIC246 is safe and efficacious in lowering the chances of the cytomegalovirus becoming active again and causing illness after an HBPC transplant (allogeneic stem cell transplant).</brief_summary>
	<brief_title>Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients</brief_title>
	<detailed_description />
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Seropositive for HCMV IgG antibodies before transplantation First allogeneic Human blood precursor cell (HBPC) transplantation performed for 1 of the following diagnoses: leukaemia, lymphoma, Hodgkin's lymphoma, nonHodgkin's lymphoma, multiple myeloma, myelodysplastic and myeloproliferative disorder Evidence of post transplantation engraftment Able to swallow tablets. Previous antiHCMV therapy after this allogeneic HBPC transplantation Mismatched or cord blood transplant recipients Current or history of endorgan HCMV disease Graft versus host disease (GVHD) Impaired liver function Reduced renal function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>HCMV</keyword>
</DOC>